Johnson & Johnson's (JNJ) Strong Earnings Report Surpasses Expectations

Core Insights - Johnson & Johnson (JNJ) reported earnings per share of $2.46, exceeding estimates of $2.43, and revenue of approximately $24.56 billion, surpassing the estimated $24.16 billion [1][5] Group 1: Financial Performance - The company's revenue increased by 9% during the fourth quarter, driven primarily by its cancer and autoimmune drug segments [2][5] - JNJ is positioned to potentially reach $100 billion in revenue next year as part of a new strategic initiative [2] - Despite a drug pricing deal with the Trump administration expected to impact profits by "hundreds of millions of dollars," JNJ remains optimistic about its 2026 sales and profit projections [2] Group 2: Financial Metrics - JNJ has a price-to-earnings (P/E) ratio of approximately 21.10, indicating the price investors are willing to pay for each dollar of earnings [3][5] - The price-to-sales ratio is about 5.71, reflecting the value placed on each dollar of sales [3][5] - The enterprise value to sales ratio stands at around 6.00, suggesting the company's total valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is approximately 22.86, showing how the company's valuation compares to its cash flow from operations [4] - JNJ has an earnings yield of about 4.74%, providing a return on investment for shareholders [4] - The company's debt-to-equity ratio is approximately 0.58, indicating a moderate level of debt relative to equity [4] - A current ratio of around 1.07 suggests JNJ's ability to cover short-term liabilities with short-term assets [4]